Effectiveness of antenatal intravenous immunoglobulin treatment in recurrent fetal and neonatal alloimmune thrombocytopenia.

ABSTRACT:

Objective

To evaluate the effectiveness of antenatal intravenous immunoglobulin (IVIG) treatment for recurrent fetal and neonatal alloimmune thrombocytopenia (FNAIT) and to determine factors associated with a good response to treatment.

Methods

This was a retrospective cohort study of pregnant women diagnosed with FNAIT and managed at a single tertiary referral center between 1992 and 2024. Affected pregnancies were treated non-invasively with weekly IVIG (1 g/kg maternal body weight) from 18-24 weeks until delivery, without platelet count monitoring. All cases were monitored with serial ultrasound for intracranial hemorrhage (ICH). Fetal blood sampling was offered at 37 weeks' gestation to determine the mode of delivery; vaginal delivery was allowed when the fetal platelet

SUBMITTER: Zloto K 

PROVIDER: S-EPMC12671933 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature